FGFR2 and neoplasm: iCCAs have a greater rate of potentially actionable genetic abnormalities than many other tumours, evidenced by recent positive trials for patients whose tumours have IDH1 mutations or FGFR2 fusions, and we recommend that molecular testing for any abnormality with potential therapeutic significance be undertaken.